Anti-tumor activity of PI3K-δ inhibitor in hematologic malignant cells: Shedding new light on resistance to Idelalisib.

[1]  D. Bashash,et al.  Inhibitor of pan class-I PI3K induces differentially apoptotic pathways in acute leukemia cells: Shedding new light on NVP-BKM120 mechanism of action. , 2016, The international journal of biochemistry & cell biology.

[2]  A. Johnson,et al.  Targeted therapies in CLL: mechanisms of resistance and strategies for management. , 2015, Blood.

[3]  Yoonjin Cho,et al.  Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma. , 2014, Blood.

[4]  Jay Patrick Lopez,et al.  Idelalisib for the treatment of indolent non-Hodgkin's lymphoma. , 2014, Drugs of today.

[5]  E. Campo,et al.  The phosphatidylinositol-3-kinase inhibitor NVP-BKM120 overcomes resistance signals derived from microenvironment by regulating the Akt/FoxO3a/Bim axis in chronic lymphocytic leukemia cells , 2013, Haematologica.

[6]  J. Ko,et al.  Dual inhibitor of phosphoinositide 3-kinase/mammalian target of rapamycin NVP-BEZ235 effectively inhibits cisplatin-resistant urothelial cancer cell growth through autophagic flux. , 2013, Toxicology letters.

[7]  J. Byrd,et al.  Final results of a phase I study of idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase P110δ (PI3Kδ), in patients with relapsed or refractory mantle cell lymphoma (MCL). , 2013 .

[8]  Mei Wu,et al.  Novel agents for chronic lymphocytic leukemia , 2013, Journal of Hematology & Oncology.

[9]  M. Brown,et al.  A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer , 2013, Journal of Hematology & Oncology.

[10]  N. Normanno,et al.  The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches , 2012, Expert opinion on therapeutic targets.

[11]  W. Yung,et al.  Antitumor Activity of NVP-BKM120—A Selective Pan Class I PI3 Kinase Inhibitor Showed Differential Forms of Cell Death Based on p53 Status of Glioma Cells , 2011, Clinical Cancer Research.

[12]  M. Keating,et al.  The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. , 2011, Blood.

[13]  J. Blenis,et al.  The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. , 2011, Trends in biochemical sciences.

[14]  R. Ulrich,et al.  Phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110d, in patients with previously treated chronic lymphocytic leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  R. Ulrich,et al.  CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. , 2011, Blood.

[16]  R. Ulrich,et al.  Clinical Pharmacokinetics of CAL-101, a p110δ Isoform-Selective PI3K Inhibitor, Following Single- and Multiple-Dose Administration In Healthy Volunteers and Patients with Hematological Malignancies , 2010 .

[17]  N. Schmitz,et al.  CNS Disease In Younger Patients ( , 2010 .

[18]  Benjamin Markman,et al.  Status of PI3K inhibition and biomarker development in cancer therapeutics. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  Pixu Liu,et al.  Targeting the phosphoinositide 3-kinase pathway in cancer , 2009, Nature Reviews Drug Discovery.

[20]  Jian Yu,et al.  PUMA, a potent killer with or without p53 , 2008, Oncogene.

[21]  L. Cantley,et al.  Ras, PI(3)K and mTOR signalling controls tumour cell growth , 2006, Nature.

[22]  R. Stahel,et al.  ΔNp73 antisense activates PUMA and induces apoptosis in neuroblastoma cells , 2005, Journal of Neuro-Oncology.

[23]  Brian J. Smith,et al.  Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. , 2005, Molecular cell.

[24]  Ying Huang,et al.  Down‐regulation of p21WAF1 promotes apoptosis in senescent human fibroblasts: Involvement of retinoblastoma protein phosphorylation and delay of cellular aging , 2004, Journal of cellular physiology.

[25]  J. Ptak,et al.  High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.

[26]  P. Dennis,et al.  Activation of the PI3K/Akt pathway and chemotherapeutic resistance. , 2002, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[27]  J. Massagué,et al.  Myc suppression of the p21Cip1 Cdk inhibitor influences the outcome of the p53 response to DNA damage , 2002, Nature.

[28]  J. Litz,et al.  Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy. , 2002, Molecular cancer therapeutics.

[29]  R. Bataille,et al.  Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. , 2002, Blood.

[30]  R. Perry,et al.  Role of c-myc in tamoxifen-induced apoptosis estrogen-independent breast cancer cells. , 1996, Journal of the National Cancer Institute.

[31]  M. Hande,et al.  hTERT overexpression alleviates intracellular ROS production, improves mitochondrial function, and inhibits ROS-mediated apoptosis in cancer cells. , 2011, Cancer research.

[32]  Jeffrey A Jones,et al.  Phosphatidylinositol 3-kinase- inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals , 2010 .

[33]  J. Nuss,et al.  Chapter 17 Emerging Therapies Based on Inhibitors of Phosphatidyl-Inositol-3-Kinases , 2009 .